Therma Bright Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Rob Fia
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 345 Danforth Avenue Toronto ON Canada M4K 1N7
- IPO Date
- May 24, 2001
- Website
- thermabright.com
- Similar Companies
- Business
- Therma Bright Inc. (TSXV:THRM) develops, acquires, manufactures and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health and consumer medical devices for consumers and institutional markets worldwide. The company offers Venowave, a medical compression pump that treats poor circulation, prevents blood clots and alleviates post-thrombotic syndrome; InterceptCS, a cold sore prevention system using controlled topical heat and light to kill virally infected cells; Benepod, a hot and cold contrast therapy device for pain relief; TherOZap, a thermal therapy device that reduces inflammation, pain, itching from insect bites and stings; AcuVid, rapid antigen and antibody screening tests for COVID-19; Digital Cough Analyzer, an AI-powered app for detecting respiratory diseases including COVID-19 via cough analysis; and investments in InStatin's inhaled statin therapy for COVID-19 pneumonia and ARDS, plus Inretio's PREVA clot retriever for ischemic stroke treatment. Founded in 2010 and headquartered in Toronto, Canada, Therma Bright operates primarily in North America with expansion into U.S. markets. Recent developments include closing a $1 million CAD private placement in June 2024 to fund Digital Cough Analyzer and InStatin investments; expanding U.S. distribution partnership with Gen-X Med for Venowave in September 2025; securing an initial exclusive U.S. marketing contract with Global Wellness Products for consumer devices in March 2025; advancing FDA 513(g) submission for Digital Cough Analyzer as remote therapeutic monitoring; pursuing permanent HCPCS and CPT codes for Venowave; and completing a 1:8 share consolidation in July 2025.
Company News
Therma Bright Inc. Completes Debt Settlements
Therma Bright Announces Expanded U.S. Orders for Venowave and Mobilizes Supply Chain for Upcoming Sales Volume
Therma Bright Announces Follow-On Order from Horizon Health as Venowave(TM) Gains Traction in U.S. Vascular Markets
Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually
Therma Bright Grants Stock Options
Therma Bright Portfolio Update: Inretio Successfully Completes First-in-Human Cohort for PREVA(TM) Stroke Platform; Targets 2026 U.S. FDA Trial
Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med
Therma Bright Inc. Investee Company, InStatin Expands its Inhaled Statin Programs to include COPD (Chronic Obstructive Pulmonary Disease) as its Lead Indication.
Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors
Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) Sales
Therma Bright Proposes to Amend Certain Warrants
Therma Bright Announces Share Consolidation
Therma Bright Inc. Announces Share Consolidation
Therma Bright Proposes to Amend Certain Warrants and Negotiates Debt Settlements
Therma Bright Inc. Provides Update on InStatin Development, Announcement of Key Strategic Advisor and Highlights Preclinical and IP Progress at InStatin
Therma Bright Secures New Customer Initial Purchase Order, Signaling Market Confidence
Therma Bright Reviews Manufacturing Strategy in Light of US Tariff Changes
Therma Bright Secures an Initial Limited Exclusive U.S. Marketing and Distribution Contract for Its Consumer Products with Global Wellness Products LLC
Therma Bright Welcomes Healthcare and Technology Expert Steve Raysely to its Advisory Board
Therma Bright Secures Purchase Order For 1,750 Venowave W5 Units From National Distributor - DME Authority of Nashville, TN